In conclusion, CEUS-guided MWA that integrates specific CEUS findings—particularly hemodynamic patterns—with serological tumor biomarkers such as AFP and DCP can significantly improve complete tumor ablation rates and reduce the local recurrence risk, offering an optimized strategy for minimally invasive treatment of HCC. The gene discussed is ACE; the disease is hepatocellular carcinoma.